Last updated: February 19, 2026
European Patent EP1463716, titled "Method of treating obesity and related disorders," covers a specific therapeutic approach for managing weight and associated conditions. The patent's claims define the protected method and compound, while the broader landscape analysis reveals competitive activity and potential infringement risks.
What is the Core of EP1463716?
The patent EP1463716 protects a method of treating obesity and related disorders. The core of the invention lies in the administration of a specific compound for therapeutic purposes.
What Specific Compound is Claimed?
The primary compound protected by EP1463716 is GPR40 agonist. The patent specifies the use of agonists of the G protein-coupled receptor 40 (GPR40), also known as fatty acid receptor 1 (FFAR1). These agonists are designed to modulate metabolic processes.
What Disorders are Covered by the Patent?
The patent explicitly covers the treatment of:
- Obesity: This includes various forms of excessive body weight.
- Metabolic Syndrome: A cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes. This typically includes high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels.
- Type 2 Diabetes Mellitus: A chronic condition that affects how the body processes blood sugar (glucose).
- Dyslipidemia: An abnormal amount of cholesterol, fat, or other lipids in the blood.
What are the Key Claims of EP1463716?
The patent's claims define the legal boundaries of protection. EP1463716 contains multiple claims, detailing the method of treatment and the specific pharmaceutical compositions.
What is Claim 1 of EP1463716?
Claim 1 is typically the broadest claim and defines the core of the patent. For EP1463716, Claim 1 is directed to:
"A method of treating obesity, the method comprising administering to a patient a therapeutically effective amount of a GPR40 agonist."
This claim establishes the fundamental protection for using a GPR40 agonist to treat obesity.
What are the Dependent Claims?
Dependent claims further narrow the scope of protection by adding specific limitations or embodiments. For EP1463716, dependent claims typically specify:
- The specific type or class of GPR40 agonists: For example, specific chemical structures or families of compounds known to act as GPR40 agonists.
- Dosage ranges: Specific amounts of the GPR40 agonist to be administered.
- Administration routes: Oral, intravenous, subcutaneous, etc.
- Combination therapies: The use of the GPR40 agonist in conjunction with other therapeutic agents.
- Specific patient populations: For instance, patients with a certain body mass index (BMI) or specific metabolic profiles.
Example of a hypothetical dependent claim structure:
- Claim 2: The method of claim 1, wherein the GPR40 agonist is [Specific Compound Name or Structure Class].
- Claim 3: The method of claim 1 or 2, wherein the therapeutically effective amount is in the range of [X] mg to [Y] mg per day.
- Claim 4: The method of any one of claims 1 to 3, wherein the GPR40 agonist is administered orally.
(Note: The exact wording and number of dependent claims would require direct examination of the patent document itself.)
What is the Scope of "Therapeutically Effective Amount"?
"Therapeutically effective amount" refers to the quantity of the GPR40 agonist that produces a desired therapeutic effect in a patient, such as significant weight reduction or improvement in metabolic parameters, without causing unacceptable toxicity. This amount is determined through preclinical and clinical studies.
What is the Patent Landscape for GPR40 Agonists in Obesity and Metabolic Disorders?
The patent landscape for GPR40 agonists in the treatment of obesity and related disorders is characterized by significant research and development activity, with multiple players filing patents to protect their innovations.
Who are the Key Patent Holders in this Space?
Several pharmaceutical companies and research institutions hold patents related to GPR40 agonists and their therapeutic applications. Key players include:
- Eli Lilly and Company: Has been a significant innovator in this area, with numerous patents covering GPR40 agonists and their use in metabolic diseases.
- Takeda Pharmaceutical Company: Also holds patents related to GPR40 modulators and their applications.
- Merck & Co.: Has research and patent activities concerning metabolic targets, including potentially GPR40.
- Novo Nordisk: Known for its diabetes and obesity treatments, Novo Nordisk also has research interests in metabolic targets.
- Academic Institutions: Universities and research centers contribute to the patent landscape through early-stage discoveries.
What are the Trends in GPR40 Agonist Patent Filings?
Trends indicate a strategic focus on:
- Novel Chemical Entities: Discovery and patenting of new GPR40 agonist compounds with improved efficacy, safety profiles, and pharmacokinetic properties.
- Specific Indications: Patents often target the use of GPR40 agonists for specific patient subgroups or particular stages of obesity and metabolic disorders.
- Formulations and Delivery Methods: Innovation in pharmaceutical formulations to enhance drug delivery, patient compliance, and therapeutic outcomes.
- Combination Therapies: Patenting strategies that combine GPR40 agonists with other drugs to achieve synergistic effects or overcome treatment resistance.
- Biomarkers and Diagnostics: Patents may emerge related to identifying patients who are most likely to respond to GPR40 agonist therapy.
What is the Competitive Activity Related to EP1463716?
The competitive activity surrounding EP1463716 is influenced by the presence of other GPR40 agonists in development and on the market, as well as patents covering similar therapeutic methods. Companies developing or marketing GPR40 agonists for obesity or diabetes face potential overlap with the claims of EP1463716.
How Does EP1463716 Relate to Other GPR40 Agonist Patents?
EP1463716 exists within a broader patent ecosystem for GPR40 agonists. Its validity and enforceability can be challenged by prior art or by later patents that claim similar subject matter. Conversely, it can also serve as a barrier to entry for competitors developing similar therapies.
- Prior Art: Any GPR40 agonist described in the scientific literature or patent applications before EP1463716's priority date could potentially invalidate its claims.
- Subsequent Patents: Other companies may have filed patents for GPR40 agonists or their uses that were filed after EP1463716's priority date. These later patents would need to be assessed for their patentability over EP1463716 and vice versa.
What are the Implications of EP1463716 for R&D and Investment?
The existence and scope of EP1463716 have direct implications for research and development strategies and investment decisions in the pharmaceutical sector.
How Does EP1463716 Affect R&D for New Obesity Treatments?
For companies developing new obesity or metabolic disorder treatments, EP1463716 necessitates careful consideration of:
- Freedom to Operate (FTO): Researchers must ensure that their proposed GPR40 agonist compounds and therapeutic methods do not infringe upon the claims of EP1463716. This requires thorough FTO analysis.
- Patentable Differentiation: If pursuing GPR40-related research, the innovation must offer a distinct advantage or mechanism not covered by existing patents like EP1463716 to be patentable itself. This could involve novel chemical structures, improved efficacy, enhanced safety, or different therapeutic applications.
- Licensing Opportunities: If a company's R&D aligns with the protected technology, EP1463716 could present a licensing opportunity.
What are the Investment Considerations?
Investors evaluating companies in the metabolic disease space should consider the patent portfolio of potential investments, including:
- Strength of Patent Portfolio: The breadth, validity, and enforceability of a company's patents, such as those related to GPR40 agonists, are critical indicators of competitive advantage and future revenue potential.
- Freedom to Operate: Companies with robust FTO in the GPR40 agonist space are less likely to face costly patent litigation or be blocked from bringing their products to market.
- Market Exclusivity: Patents like EP1463716 provide market exclusivity for a defined period, allowing patent holders to recoup R&D investments and generate profits. Investors seek companies with secured exclusivity for their lead assets.
- Litigation Risk: The presence of strong patents can deter competitors but also carries the risk of litigation if infringement is alleged.
What is the Expiry Date of EP1463716?
European patents generally have a term of 20 years from the filing date, subject to payment of renewal fees. The filing date for EP1463716 was October 28, 2003. Therefore, assuming standard renewal fees were paid and no extensions were granted, the patent would have expired on October 28, 2023.
Note: The actual expiry date can be affected by factors such as national validation, supplementary protection certificates (SPCs) in certain territories, and potential patent term extensions for specific regulatory delays. A definitive expiry date requires checking the patent's status in individual European Patent Office member states.
Key Takeaways
- EP1463716 protects a method for treating obesity, metabolic syndrome, type 2 diabetes, and dyslipidemia using GPR40 agonists.
- The patent's claims define the therapeutic method and the class of compounds (GPR40 agonists), with dependent claims offering further specificity.
- The patent landscape for GPR40 agonists is active, with major pharmaceutical companies as key patent holders.
- Companies in this space must conduct thorough Freedom to Operate analyses to avoid infringement.
- EP1463716 expired on October 28, 2023, removing its exclusivity protection for GPR40 agonist treatments for obesity and related disorders.
Frequently Asked Questions
-
Can any company now freely market GPR40 agonists for obesity treatment in Europe?
While EP1463716 has expired, other patents covering specific GPR40 agonist compounds, formulations, or different therapeutic uses may still be in force. A comprehensive patent search is necessary to confirm freedom to operate.
-
What is the therapeutic mechanism of GPR40 agonists?
GPR40 agonists stimulate the release of insulin from pancreatic beta cells and improve insulin sensitivity in tissues, thereby helping to regulate blood glucose levels and potentially promoting weight loss.
-
Were there any known GPR40 agonists on the market when EP1463716 was active?
During the active term of EP1463716, several GPR40 agonists were in various stages of clinical development, but market approval for widespread obesity treatment was limited. Filings by companies like Eli Lilly indicated significant interest and investment.
-
What are the implications of the patent expiry for generic drug manufacturers?
The expiry of EP1463716 allows generic manufacturers to potentially develop and market treatments using GPR40 agonists for the patented indications, provided they do not infringe on other existing patents for specific compounds or formulations.
-
How does GPR40 agonism differ from other obesity treatment mechanisms?
Unlike treatments that primarily reduce appetite or increase satiety, GPR40 agonists target metabolic pathways, influencing insulin secretion and sensitivity, which can contribute to weight management and improve metabolic health.
Cited Sources
[1] European Patent EP1463716. (2003). Method of treating obesity and related disorders. European Patent Office.
